MEDIA
Want to find out what’s happening with us?
Here’s the latest buzz…
MAY, 2024
Somerset Pharma announces launch of Cupric Chloride Injection, USP One of few companies to receive CGT status for product.
We are delighted to share that Somerset has received approval for and launched Cupric Chloride Injection, USP. This product is one of the first launches planned in the next quarter and for the rest of the year. The launch of Cupric Chloride Injection, USP, marks a further advancement in the company’s pharmaceutical portfolio and our aim of launching more products that have continued to have supply issues.
Manufactured in our state-of-the-art facility, the launch of Cupric Chloride underscores the company’s commitment to making quality generics available at affordable prices. Somerset had received CGT status for the product and will be among the few generics in the market. We are now poised to launch a pipeline of 20-30 additional products post approval, from the same facility.
“We are dedicated to delivering high-quality generics at affordable prices, benefiting our healthcare partners and the patients they serve. The expedited approval of our first CGT product within just two days is a testament to the dedication and expertise of our team.”
– Dr. Veerappan Subramanian
Chairman & CEO, Somerset Pharma
Cupric Chloride Injection, USP, a sterile and non-pyrogenic solution, is designed as an adjunct to intravenous solutions for total parenteral nutrition (TPN). Its administration aids in maintaining optimal copper serum levels, mitigating the risk of depletion and associated deficiency symptoms.
We take this opportunity to thank our healthcare partners for your constant support and faith in the company. We look forward to achieving and celebrating many new milestones together.